TenNor Therapeutics has a unique multi-targeting drug conjugate technology platform-a fully integrated R&D engine that drives innovation. All of TenNor’s drug candidates are conjugated molecules with multi-targeting mechanism of action, developed through this platform. It spans the full spectrum of drug design, synthesis, and evaluation, specifically focused on candidates targeting bacterial infections and bacterial metabolism. The primary goal in developing this platform is to address the critical challenges in antibacterial drug development, namely, antimicrobial resistance and antimicrobial tolerance. With this platform, TenNor Therapeutics carefully selects potential targets, design and synthesize conjugate molecules, and iteratively fine-tune the molecular structure based on evaluation results.